biostudies-literatureUnknown25(1)Kuang L<h4>Background</h4>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the established first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, but survival advantages in advanced-stage cases remain modest and show interpatient variability. This study seeks to delineate real-world survival outcomes in stage IV EGFR-mutant NSCLC patients undergoing treatment with EGFR-TKIs and to identify independent prognostic factors impacting overall survival (OS). The findings are expected to be a reference for clinicians in managing advanced lung cancer patients.<h4>Methods</h4>Clinical characteristics from advanced EGFR-mutant NSCLC patients who received EGFR-TKIs were retrospectively analyzed to investigate thBMC pulmonary medicine114https://www.ebi.ac.uk/biostudies/studies/S-EPMC11907820biostudies-literaturePrognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs.PMC11907820Li YWang PZhang YKuang LWang HfalsePrognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs.<h4>Background</h4>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the established first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, but survival advantages in advanced-stage cases remain modest and show interpatient variability. This study seeks to delineate real-world survival outcomes in stage IV EGFR-mutant NSCLC patients undergoing treatment with EGFR-TKIs and to identify independent prognostic factors impacting overall survival (OS). The findings are expected to be a reference for clinicians in managing advanced lung cancer patients.<h4>Methods</h4>Clinical characteristics from advanced EGFR-mutant NSCLC patients who received EGFR-TKIs were retrospectively analyzed to investigate th2025-01-01T00:00:00Z2025 Mar2025-04-04T00:32:47.901Z2025-04-04T00:32:47.901ZS-EPMC119078204008291810.1186/s12890-025-03569-1